Can genes predict chemo success in pancreatic cancer?

NCT ID NCT03977233

First seen Oct 31, 2025 · Last updated Jun 16, 2026 · Updated 26 times

Summary

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (like basal-like or classical) influence how well the cancer shrinks or becomes removable. The goal is to improve disease control and surgical outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.